T. Collon

677 total citations
22 papers, 374 citations indexed

About

T. Collon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, T. Collon has authored 22 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in T. Collon's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (10 papers). T. Collon is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (10 papers). T. Collon collaborates with scholars based in France, Belgium and United Kingdom. T. Collon's co-authors include M Grivaux, F Blanchon, D. Coëtmeur, Mahmoud Zureik, Bernard Asselain, B. Delclaux, J. Le Treut, Olivier Molinier, Abdoulaye Karaboué and Ida Pavese and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

T. Collon

21 papers receiving 367 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Collon France 11 249 200 57 49 48 22 374
J Schmerber Belgium 12 279 1.1× 83 0.4× 27 0.5× 117 2.4× 6 0.1× 25 353
Fangyong Li United States 7 103 0.4× 84 0.4× 35 0.6× 26 0.5× 7 0.1× 15 282
Joohyun Woo South Korea 10 85 0.3× 64 0.3× 17 0.3× 50 1.0× 6 0.1× 36 305
Yasuto Nakatsumi Japan 11 284 1.1× 102 0.5× 22 0.4× 169 3.4× 32 0.7× 26 402
Clare Byrne United Kingdom 10 97 0.4× 147 0.7× 56 1.0× 34 0.7× 9 0.2× 25 315
Hiroaki Kikukawa Japan 9 55 0.2× 30 0.1× 46 0.8× 16 0.3× 14 0.3× 21 210
Nadia Birocco Italy 10 49 0.2× 227 1.1× 177 3.1× 41 0.8× 2 0.0× 14 347
Andrew M. Wilhelm Germany 4 256 1.0× 11 0.1× 23 0.4× 89 1.8× 24 0.5× 8 313
André Oberthür Germany 5 66 0.3× 35 0.2× 17 0.3× 11 0.2× 16 0.3× 11 203
Paolo Beck‐Peccoz Italy 9 20 0.1× 59 0.3× 40 0.7× 48 1.0× 79 1.6× 10 416

Countries citing papers authored by T. Collon

Since Specialization
Citations

This map shows the geographic impact of T. Collon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Collon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Collon more than expected).

Fields of papers citing papers by T. Collon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Collon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Collon. The network helps show where T. Collon may publish in the future.

Co-authorship network of co-authors of T. Collon

This figure shows the co-authorship network connecting the top 25 collaborators of T. Collon. A scholar is included among the top collaborators of T. Collon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Collon. T. Collon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lévi, Françis, Zhe Huang, Abdoulaye Karaboué, et al.. (2025). Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.. Journal of Clinical Oncology. 43(16_suppl). 2510–2510.
2.
Karaboué, Abdoulaye, T. Collon, Pasquale F. Innominato, et al.. (2023). Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). e21055–e21055. 3 indexed citations
3.
Karaboué, Abdoulaye, T. Collon, Ida Pavese, et al.. (2021). Time-dependent efficacy of checkpoint inhibitor nivolumab in metastatic lung cancer patients.. Journal of Clinical Oncology. 39(15_suppl). 9096–9096. 1 indexed citations
4.
Karaboué, Abdoulaye, et al.. (2020). Circadian variation in nivolumab efficacy in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). e21585–e21585. 6 indexed citations
5.
Pavese, Ida, et al.. (2018). Impact on treatment adherence, side effects control, patients QoL, and rehospitalization rate through new management of oral chemotherapy.. Journal of Clinical Oncology. 36(15_suppl). e18533–e18533. 3 indexed citations
6.
Grivaux, M, François Goupil, Bernard Asselain, et al.. (2017). Stratégies thérapeutiques les 2 premières années après un diagnostic de cancer du poumon. ESCAP-2011-CPHG, étude en situation réelle réalisée dans les hôpitaux généraux français. Revue des Maladies Respiratoires. 34(9). 991–999. 7 indexed citations
7.
Locher, Chrystèle, D. Debieuvre, D. Coëtmeur, et al.. (2013). Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies. Lung Cancer. 81(1). 32–38. 74 indexed citations
8.
Grivaux, M, P. Bombaron, Bernard Asselain, et al.. (2012). Étude KBP-2010-CPHG : description de 7414 nouveaux cas de cancer bronchopulmonaire primitif (CBP) pris en charge dans les hôpitaux généraux en 2010. Revue des Maladies Respiratoires. 29. A26–A26. 1 indexed citations
9.
10.
Sculier, Jean‐Paul, J.J. Lafitte, Marianne Paesmans, et al.. (2007). Chemotherapy improves low performance status lung cancer patients. European Respiratory Journal. 30(6). 1186–1192. 20 indexed citations
11.
Berghmans, T., J.J. Lafitte, J. Lecomte, et al.. (2007). Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. British Journal of Cancer. 96(11). 1644–1649. 10 indexed citations
12.
Sculier, Jean‐Paul, J.J. Lafitte, J. Lecomte, et al.. (2007). A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Annals of Oncology. 18(6). 1037–1042. 18 indexed citations
13.
Blanchon, F, M Grivaux, Mahmoud Zureik, et al.. (2006). CohorteKbp-2000-Cphg : évaluation des facteurs pronostiques de la survie du cancer bronchique primitif à 2 et 5 ans. Revue des Maladies Respiratoires. 23(2). 165–171. 12 indexed citations
14.
Berghmans, T., J.J. Lafitte, Marianne Paesmans, et al.. (2005). A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer. 50(1). 75–82. 22 indexed citations
15.
Collon, T., M Grivaux, P. Doré, et al.. (2004). Le cancer bronchique primitif non à petites cellules : analyse des 419 cas de tumeurs T1 (≤ 3 cm) de l’étude KBP-2000-CPHG. Revue de Pneumologie Clinique. 60(6). 333–343. 3 indexed citations
16.
Piquet, J., F Blanchon, M Grivaux, et al.. (2004). Le cancer bronchique primitif du sujet âgé en France. Revue des Maladies Respiratoires. 21(5). 70–78. 9 indexed citations
17.
Blanchon, F, M Grivaux, T. Collon, et al.. (2004). [Primary lung cancer in elderly subjects in France].. PubMed. 21(5 Pt 3). 8S70–8. 12 indexed citations
18.
Blanchon, F, M Grivaux, T. Collon, et al.. (2003). [Primary bronchial carcinoma in elderly subjects in France].. PubMed. 20(5 Pt 1). 691–9. 12 indexed citations
19.
Blanchon, F, M Grivaux, T. Collon, et al.. (2002). [Epidemiologic of primary bronchial carcinoma management in the general French hospital centers].. PubMed. 19(6). 727–34. 66 indexed citations
20.
Collon, T., et al.. (1999). Polyarthralgia-arthritis syndrome induced by low doses of rifabutin.. PubMed. 26(5). 1201–2. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Schmerber Breakdown of academic impact, for papers by Fangyong Li Breakdown of academic impact, for papers by Joohyun Woo Breakdown of academic impact, for papers by Yasuto Nakatsumi Breakdown of academic impact, for papers by Clare Byrne Breakdown of academic impact, for papers by Hiroaki Kikukawa Breakdown of academic impact, for papers by Nadia Birocco Breakdown of academic impact, for papers by Andrew M. Wilhelm Breakdown of academic impact, for papers by André Oberthür Breakdown of academic impact, for papers by Paolo Beck‐Peccoz
Rankless by CCL
2026